Patent intelligence · US
US 7309702
Arylpiperazines having activity at the serotonin 1A receptor
Arylpiperazines having activity at the serotonin 1A receptor
Patent details — US 7309702
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 18, 2007
- Expiration
- Dec 13, 2027
- Applicant
- Avera Pharmaceuticals, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K31/495, A61K31/496, A61P
Quick answer
US 7309702 (Arylpiperazines having activity at the serotonin 1A receptor) is held by Avera Pharmaceuticals, Inc.. Status: granted. Granted Dec 18, 2007. Expires Dec 13, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Avera Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/495, A61K31/496, A61P, A61P1/00, A61P15/10
More from Avera Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 7309702?
US 7309702 (Arylpiperazines having activity at the serotonin 1A receptor) is held by Avera Pharmaceuticals, Inc.. Status: granted. Granted Dec 18, 2007. Expires Dec 13, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7309702?
Avera Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 7309702 expire?
Our index shows an expiration date of Dec 13, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.